When credibility is critical, choose a partner that inspires confidence.

When complex financial problems arise, Gleason Experts helps clients minimize risk exposure, consider alternative scenarios, project results and take advantage of strategic opportunities.

Gleason IP takes a client-focused, cost-effective approach to IP issues, delivering insightful economic and financial analyses across a range of industries, with particular knowledge/expertise in Pharma/Life Sciences.

Gleason Trust has decades of experience in trust accounting, trust management and administration, and providing high-quality service to meet the fiduciary needs of a variety of trusts.

Gleason Advisors provides valuable financial and strategic advice to closely held, private companies throughout the business life cycle. Our experience spans multiple industries and challenges.


Value Beyond Dispute

Gleason is committed to providing honest, independent, objective opinions on financial and economic issues, supported by thoughtful, thorough analysis and relevant, reliable data. Our unmatched experience and integrity repeatedly produce results that withstand detailed – and often ruthless – examination.
Since 1988, our clients have found exceptional value in our insights. We are a trusted and proven partner in disputed, high risk scenarios that require specialized valuation and financial analysis.
Thousands of clients across the nation rely on our proficiency in accounting, tax, finance and economics. Our seasoned professionals hold credentials including CPA, CFA, CFE and MBA, and their expertise is widely recognized.

News and Press

Gleason IP News & Updates

October 2, 2023

Delaware Chief Judge Connolly Credits Ivan Hofmann’s Commercial Success Testimony in a Pharmaceutical Patent Case   Gleason IP was retained by multiple defendants in a patent infringement matter related to Taiho Pharmaceutical Co., Ltd. and Taiho Oncology, Inc.’s Lonsurf® (trifluridine and tipiracil) tablets.  Lonsurf® tablets are a prescription medicine for stomach cancer (sometimes referred to...   Read More

Gleason IP News & Updates

July 20, 2023

Federal Circuit Affirms the Use of Blocking Patents in a Commercial Success Inquiry In the patent litigation between UCB and Actavis related to the reformulated Neupro® patch, the Federal Circuit affirmed the District Court’s decision regarding Ivan Hofmann’s testimony related to blocking patents that dissuaded competitors from developing a rotigotine patch that practiced the claimed...   Read More

Find out about Careers at Gleason

We’re always on the lookout for talented new additions to the Gleason team.

Learn More